U
Build Your Knowledge
Pharmacology logicUro-oncology / Pharmacology

Intravesical Therapy

Intravesical therapy treats non-muscle-invasive bladder cancer in the bladder itself — a single chemotherapy instillation reduces recurrence, while BCG immunotherapy (induction + maintenance) treats high-risk disease.

Tools
chemo vs BCG
+
BCG
induction + maintenance
+
Fail
consider cystectomy
Orientation

The big picture

Two tools delivered into the bladder. Chemotherapy (e.g. mitomycin) is cytotoxic and, given as a single early instillation after TURBT, lowers recurrence in low/intermediate-risk disease. BCG is a live immunotherapy that provokes a local immune response and, with maintenance, reduces recurrence and progression in high-risk NMIBC and CIS.

Golden rule

Right agent for the risk: single chemo instillation for low risk, BCG induction + maintenance for high risk — and never instil BCG into a traumatised or actively infected/bleeding bladder.

Pathophysiology

Mechanism pathway

Tap any step to see why it happens.

Pharmacology

Drug selector

Single chemo instillation (mitomycin)

Low risk
Targets
Direct cytotoxicity on residual cells
Onset
Immediate (peri-operative)
Use when
A single early post-TURBT instillation to reduce recurrence in low/intermediate-risk NMIBC
Side effects
Chemical cystitis; avoid with bladder perforation
Board trap: Do not instil if there is a suspected bladder perforation
Safety

Complications

Disease complications
  • Recurrence and progression if undertreated
Treatment complications
  • Chemical cystitis (chemotherapy)
  • BCG cystitis, flu-like illness
  • Systemic BCG infection (BCGosis) — a medical emergency
  • BCG sepsis after traumatic instillation
How to prevent
  • Never instil BCG with traumatic catheterisation, gross haematuria or active UTI
  • Avoid chemotherapy instillation if perforation is suspected
  • Counsel on symptoms of systemic BCG infection
How to manage
  • Treat BCG cystitis symptomatically
  • Systemic BCGosis: anti-tuberculous therapy and supportive care
  • Escalate BCG-unresponsive disease to cystectomy
Surveillance

Follow-up

What to monitor
  • Surveillance cystoscopy and cytology
  • Tolerance of therapy
  • Signs of BCG-unresponsive disease
Timing
  • Scheduled cystoscopic surveillance during and after therapy
Success looks like
  • No recurrence on surveillance; tolerated maintenance
Failure looks like
  • Recurrence/progression on therapy (BCG-unresponsive)
When to image
  • Surveillance; upper-tract imaging per risk
Long-term issues
  • Cumulative bladder symptoms
  • Need for cystectomy in unresponsive disease
Recall

Memory hooks

Low risk → one chemo instillation.

High risk/CIS → BCG induction + maintenance.

No BCG with trauma, gross haematuria or UTI.

BCG-unresponsive high risk → cystectomy.

Exam

Board traps

BCG instilled after a bloody traumatic catheterisation — risk of systemic BCG sepsis.

High-risk NMIBC given only a single chemo instillation — needs BCG.

BCG-unresponsive high-grade disease continued on BCG — should move to cystectomy.

Chemo instillation given despite suspected bladder perforation.

Apply

Clinical cases

Case 1

After TURBT for high-grade T1 disease and carcinoma in situ, a patient is counselled about intravesical therapy. The nurse reports a traumatic, bloody catheterisation at the planned first BCG instillation.

What is the correct action?

Test yourself

Quiz

Back to all modules